Frost & Sullivan Recognizes Piramal for its End-to-End Integrated Services Across the Entire Drug Development Life Cycle

Photo: Piramal combines individualized service with unparalleled speed and flexibility to manufacture parenteral drug products in liquid and lyophilized dosage forms. Unique mobile isolator technology within FDA-approved sterile manufacturing facility ensures product containment for potent and cytotoxic compounds and radio-labeled products. Photo courtesy: Piramal Pharma Solutions/Coldstream Laboratories, Lexington, Kentucky.
Photo: Piramal combines individualized service with unparalleled speed and flexibility to manufacture parenteral drug products in liquid and lyophilized dosage forms. Unique mobile isolator technology within FDA-approved sterile manufacturing facility ensures product containment for potent and cytotoxic compounds and radio-labeled products. Photo courtesy: Piramal Pharma Solutions/Coldstream Laboratories, Lexington, Kentucky.

Following a recent analysis of the market of contract development and manufacturing organizations (CDMO), Frost & Sullivan recognized Piramal Pharma Solutions with its 2019 Global Customer Service Leadership Award.

Through its 12 development centers and manufacturing sites across North America, Europe, and Asia, Piramal provides end-to-end capabilities to its pharmaceutical customers across the entire drug development life cycle. The company combines its global operational capabilities and standardized scheduling to minimize supply chain constraints and shorten delivery timelines for customers. Piramal also deploys an innovative quality framework across its global manufacturing network.

2019 Global Contract Development and Manufacturing Organization Customer Service Leadership Award

“In our assessment the company, with unparalleled research and development focus, strives to re-engineer its internal capabilities, programs, and new technologies to expedite a drug’s time-to-market,” noted Khushbu Jain, a Biodesign and Innovation Fellow and Industry Analyst at Frost & Sullivan.

ADC Bio
Lonza
MabPlex
 

“Piramal’s offerings include drug discovery, drug development, and drug substance and product commercial manufacturing. By having half of its manufacturing sites in the East and the other half in the West, it ensures flexible scheduling for shorter delivery timelines and significant resource and time savings,” she added.

Piramal’s R&D team resolves complex process development and formulation challenges and develops robust processes for customers. The business has proven expertise in injectable capabilities and provides complete contract development and manufacturing capabilities across active pharmaceutical ingredients (API) and formulations, including niche capabilities in handling cytotoxic injectables, hormonal formulations, and high potency APIs (HPAPIs).

In October 2018, Piramal announced the launch of its ‘Xcelerate Integrated Solutions™’ platform, addressing the growing industry need for preferred collaboration with service providers that can provide world-class solutions across the entire drug-cycle.

This Xcelerate platform offers customized integrated solutions through which its customers can accelerate their programs from clinical through approval and launch for both large volume indications and niche fast-track medicines.

Piramal’s distinct footprint allows customers to manufacture the final API or Drug products around the globe.

Vivek Sharma, Chief Executive Officer of Piramal Pharma Solutions: “We are delighted to receive this award from Frost & Sullivan, one of the industry’s most credible companies, for quality recognition.”

Antibody-drug Conjugates
In addition, as one of the world leaders in the antibody-drug conjugates (ADC) segment, the business provides integrated manufacturing solutions for ADCs, ranging from development through clinical and commercial batch manufacturing to ADC fill/finish.

Piramal is also involved in the supply of commercial ADCs on the market and is working on several Phase II and Phase III drugs designated as breakthrough therapies with multiple pharmaceutical companies.

Inspections
“With a focus on compliance, quality standards, and reliability, Piramal cleared 33 United States Food and Drug Administration (US FDA) inspections, 143 other regulatory inspections including by authorities from Europe, Canada, Brazil and Japan, and 971 customer audits across all its facilities without closing production,” Jain noted.

“Strengthening its value proposition for pharma and biotech companies, Piramal is building new capabilities in outsourcing, as well as strategic partnerships with customers. Its inorganic growth strategies and on-going investments at sites allow it to address key customer requirements and ultimately, position itself for greater growth,” she added

“We are delighted to receive this award from Frost & Sullivan, one of the industry’s most credible companies, for quality recognition,”  said Vivek Sharma, Chief Executive Officer of Piramal Pharma Solutions.

“We are committed to serving our customers and through them, the patients, with the highest standards of quality. Frost & Sullivan recognition is a validation of our commitment to be an integrated solutions provider for our customers, and our robust track record. We continue to be the ‘Partner of Choice’ for global pharmaceutical companies as we continue to invest in capacities and capabilities across our manufacturing and R&D Site,” he added.

“As a company and dedicated team we strive to  the be the committed partner helping our customers to serve the patient community and to reduce the burden of disease,” Sharma concluded.

Consistent high standards
Each year, Frost & Sullivan presents this award to the company that maintains consistently high standards for customer service quality that result in trusted and strategic relationships. Piramal is recognized as a company that leverages customer feedback, demonstrates superior speed/timeliness, ensures frictionless interaction and outstanding price/performance value, offers a rich customer purchase/ownership experience, thus raising its overall brand equity.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.